Q2 2026 saw strong organic growth, higher profitability, and robust free cash flow, led by double-digit gains in Prosthetics & Neuro Orthotics and solid performance in EMEA and APAC. Patient Care lagged but showed operational progress, while guidance was narrowed to 5%-7% organic growth for the year.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.